BMLKF.US BML, Inc.
- Market cap
- USD 945M
- P/E
- 19.1x
- P/B
- 0.90x
- ROE
- 6.2%
- Dividend yield
- 3.19%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is BMLKF.US undervalued?
Graham numberBMLKF.US trades 12.8% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BML, Inc. fundamental analysis
No fundamental analysis for BML, Inc. yet.
BML, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BML, Inc.
BML, Inc. provides contract clinical testing and related services in Japan. The company offers routine laboratory testing, such as biochemical and hematologic examination; special laboratory test, including tumor markers, infectious diseases, hormones, cellular immunity, genetics, bacteriological tests, and other test; specialized testing in oncology, infectious diseases, diabetes, hypertension, allergies, genetics, and more areas, as well as develops Frontier and Symphony a…
Full company profileBML, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
BML, Inc. annual financial statements (JPY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 139B | 186B | 159B | 138B | 143B | 150B | 156B |
| Gross Profit | 54.8B | 87.0B | 61.4B | 45.6B | 45.9B | 48.7B | 52.4B |
| Operating Income | 19.9B | 48.9B | 23.9B | 9.17B | 9.36B | 10.4B | 12.0B |
| EBITDA | - | - | 30.5B | 16.3B | 17.5B | 21.2B | 12.6B |
| Net Income | 13.7B | 33.7B | 15.6B | 6.03B | 6.26B | 7.75B | 7.92B |
| EPS | 337 | 845 | 399 | 155 | 161 | 207 | 211 |
| Balance Sheet | |||||||
| Total Assets | 139B | 179B | 169B | 171B | 178B | 183B | 180B |
| Total Liabilities | 46.1B | 57.5B | 42.2B | 40.9B | 43.7B | 51.1B | 48.4B |
| Shareholders' Equity | 93.1B | 122B | 127B | 130B | 134B | 128B | 127B |
| Cash & Short-term Investments | 63.5B | 92.1B | 86.5B | 74.1B | 67.6B | 68.0B | 53.4B |
| Cash Flow | |||||||
| Operating Cash Flow | 19.6B | 45.6B | 11.7B | 14.4B | 15.8B | 20.7B | - |
| Capital Expenditure | 4.20B | 7.09B | 6.46B | 20.9B | 16.7B | 10.1B | 0.00 |
| Free Cash Flow | 15.4B | 38.5B | 5.28B | -6.48B | -849M | 10.6B | - |
| Ratios | |||||||
| ROE | 14.7% | 27.7% | 12.3% | 4.6% | 4.7% | 6.1% | 6.2% |
| ROA | 9.9% | 18.8% | 9.2% | 3.5% | 3.5% | 4.2% | 4.4% |
| Net Profit Margin | 9.9% | 18.1% | 9.8% | 4.4% | 4.4% | 5.2% | 5.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
BML, Inc. dividends
- Dividend yield
- 3.19%
- Forward dividend
- 0.80 USD
- Payout ratio
- 64.3%
- Ex-dividend date
- Mar 30, 2027
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | JPY 4.98B | 133 | 64.3% |
| 2025 | JPY 3.51B | 90 | 56.0% |
| 2024 | JPY 3.90B | 100 | 64.6% |
| 2023 | JPY 4.96B | 127 | 31.9% |
| 2022 | JPY 3.46B | 87 | 10.2% |
| 2021 | JPY 1.83B | 45 | 13.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Aug 29, 2016.
Who owns BML, Inc.
- Insiders 42.34%
- Institutions 19.21%
- Public & others 38.45%
- Shares outstanding 37.5M
- Free float 20.6M
BML, Inc. company profile
- Company name
- BML, Inc.
- Ticker
- BMLKF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Employees
- 4,612
- Fiscal year end
- March
- Address
- 5-21-3 Sendagaya, Tokyo, Japan, 151-0051
- Phone
- 81 3 3350 0111
- Website
- bml.co.jp
About BML, Inc.
BML, Inc. provides contract clinical testing and related services in Japan. The company offers routine laboratory testing, such as biochemical and hematologic examination; special laboratory test, including tumor markers, infectious diseases, hormones, cellular immunity, genetics, bacteriological tests, and other test; specialized testing in oncology, infectious diseases, diabetes, hypertension, allergies, genetics, and more areas, as well as develops Frontier and Symphony automation systems, which automate pre-testing from specimen sorting to dispensing. It also provides contract clinical testing, including endocrine, plasma protein, biochemical, viral, immunoserological, hematological, cellular immunity, bacteriological, and histopathological, pathological, and cytological tests; specimen receiving service; and medical information system services, which include electronic medical charts for clinics without beds. In addition, the company is involved in manufacturing and supply services for medical equipment and supplies; real estate leasing and insurance agency business; providing food hygiene inspection and food consulting services; and dispensing pharmacy services. The company was incorporated in 1955 and is headquartered in Tokyo, Japan.
BML, Inc. management
7- Mr. Kensuke KondoPresident & Representative Director · born 1966
- Mr. Hideaki OsawaExec. Officer, Div Mangr of Mktg. & Dept. Mangr of Proposal & Clinical Trial Mktg and Dir · born 1964
- Mr. Nobuki AraiVP & Representative Director · born 1960
- Masami KondoSr.Mag Exec. Offi Div. Mgr of In-Hospital Testing, Dept. Mgr of 2nd In-Hospital Testing and Director · born 1965
- Mr. Kenji ShibataSenior Managing Executive Officer, Div Manager of BML Testing Division & Director · born 1959
- Mr. Yuji YamashitaExecutive Officer, Division Manager of System Division & Director · born 1965
- Hiroyuki KigoshiManaging Executive Officer